Pelayo Carolina, Ciampi Ethel, Uribe-San-Martín Reinaldo, Soler Bernardita, Reyes Ana, Vergara Elizabeth, Cárcamo Claudia
Neurology Department, Pontificia Universidad Católica de Chile, Chile.
Neurology Department, Pontificia Universidad Católica de Chile, Chile; Neurology Service, Hospital Dr. Sótero del Río, Chile.
Mult Scler Relat Disord. 2020 Oct;45:102411. doi: 10.1016/j.msard.2020.102411. Epub 2020 Jul 17.
Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema and increased risk of infections, mainly due to its main mechanism of action, the non-selective modulation of sphingosine-1-phosphate receptor.
We report the baseline characteristics, effectiveness outcomes and adverse events of a prospective cohort of 177 patients with a median treatment duration of 24 months, in which four patients (2.3%) presented with otherwise non-provoked peripheral vascular events (PVE).
Further studies are still needed to evaluate the frequency and severity of PVE in fingolimod patients.
芬戈莫德是一种用于治疗多发性硬化症（MS）的高效疾病修正疗法，是首个被批准用于该疾病的口服治疗药物。不良事件包括缓慢性心律失常、高血压、黄斑水肿以及感染风险增加，主要归因于其主要作用机制，即对1-磷酸鞘氨醇受体的非选择性调节。
我们报告了一个前瞻性队列中177例患者的基线特征、疗效结果和不良事件，这些患者的中位治疗持续时间为24个月，其中4例患者（2.3%）出现了不明原因的外周血管事件（PVE）。
仍需进一步研究以评估芬戈莫德治疗患者中PVE的发生率和严重程度。
